Why the study?
Does infusion of saralasin or SQ 20881 improve diagnostic discrimination of renovascular hypertension from essential hypertension?
Does infusion of saralasin or SQ 20881 improve diagnostic discrimination of renovascular hypertension from essential hypertension?
Testing with angiotensin blocking agents like saralasin or SQ 20881 elicits reactive hyperreninemia, serving as a highly specific secondary screening tool to differentiate renovascular from essential hypertension in patients on normal sodium intake.
Answers are grounded in this paper and cite their sources.
May support saralasin or SQ 20881 testing as a specific screen for renovascular hypertension; leaves open prospective validation before clinical adoption.
Baseline plasma renin activity and responses to saralasin and converting enzyme inhibitor SQ 20881 (teprotide) in 47 untreated patients with surgically correctable renovascular hypertension were compared to those in 100 patients with high- and normal-renin essential hypertension. All 32 renovascular patients on normal sodium intake had high renin-sodium profiles and renin values greater than or equal to 5 ng angiotensin I/mL.h, as compared to 20 of 64 with essential hypertension. Diagnostic discrimination was greatly enhanced by infusion of saralasin or SQ 20881, which elicited marked reactive hyperreninemia in 31 of 32 renovascular patients but in only two of 64 with essential hypertension. Reactive hyperreninemia appeared to be more a specific test for renovascular hypertension than depressor responses. Prior dietary sodium depletion abolished this specificity. The results suggest that after initial screening with renin measurements, testing with angiotensin blocking agents may be a useful secondary screening procedure for more invasive and definitive procedures.
No takes yet. Share an insight, caveat, or question.
David B. Case (1979) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: